(NASDAQ: GRAL) Grail's forecast annual revenue growth rate of N/A is not forecast to beat the US Diagnostics & Research industry's average forecast revenue growth rate of 9.03%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 19.72%.
Grail's revenue in 2025 is N/A.On average, 1 Wall Street analysts forecast GRAL's revenue for 2025 to be $4,691,238,984, with the lowest GRAL revenue forecast at $4,691,238,984, and the highest GRAL revenue forecast at $4,691,238,984.
In 2026, GRAL is forecast to generate $5,188,160,801 in revenue, with the lowest revenue forecast at $5,188,160,801 and the highest revenue forecast at $5,188,160,801.